Trial Profile
Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Aug 2020
Price :
$35
*
At a glance
- Drugs Susoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Sponsors Baxalta
- 16 Jul 2019 Status changed from active, no longer recruiting to completed.
- 30 Apr 2019 Planned number of patients changed from 40 to 60.
- 30 Apr 2019 Planned End Date changed from 1 Aug 2019 to 7 Jun 2019.